Albuquerque, NM, March 3, 2026 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces surpassing the 3,000th installation of HALO software worldwide. HALO software provides transformative digital pathology solutions that span the entire bench to bedside continuum, from research and discovery to clinical research and primary diagnosis applications that in turn inform research pipelines. As HALO platforms also power companion diagnostics development, software from Indica Labs comprehensively covers the entire spectrum of digital pathology applications.

Common to all HALO image analysis and image management platforms is seamless interoperability, performance, scalability, and ease of use. This unique combination of attributes has led to HALO deployments across all 20 top pharma companies, leading hospitals and cancer centers, government and nonprofit organizations, as well as biotech and academia. Deployments are geographically distributed across 35 countries spanning six continents and range from a single workstation to enterprise-wide installations serving thousands of users.

HALO platforms are cited in more than 2,600 peer-reviewed articles spanning oncology, immuno-oncology, neuroscience, infectious disease, metabolism, and other areas. Customer publications can be explored in a public-facing database that contains a myriad of search functionalities to identify specific publications of interest.

Indica Labs, a consistently profitable company since inception, recently partnered with Leica Biosystems to accelerate the distribution of HALO software and to deliver AI-powered companion diagnostics. In the first year of the partnership, the companies delivered the launch of Aperio HALO AP as well as the Aperio AI Store, containing nine AI tools from Indica Labs, and have exciting developments in store for 2026.

Indica Labs CEO Steven Hashagen commented, “we are delighted to announce the 3,000^th installation of our HALO software that powers every step of the bench to bedside to bench translational research cycle. With our partners at Leica Biosystems, we look forward to accelerating our impact by delivering novel diagnostic tools that enable patients to receive optimal therapies when faced with life changing cancer diagnoses.”

About Indica Labs:

Indica Labs, the global leader in AI-powered digital pathology, is redefining medicine with pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development. HALO platforms integrate image management and quantitative image analysis to deliver standardized, reproducible tissue-based analysis at every stage of the translational journey.

Media Contact:

Kim Collins

kcollins@indicalab.com